Harnessing the muscle of one of the world’s fastest supercomputers, researchers have built one of the largest and most detailed biophysically realistic brain simulations of an animal ever.
A new patch developed by Texas A&M University researcher Dr. Ke Huang may offer a way to help the heart heal after a heart attack. The patch uses a unique microneedle system to deliver a therapeutic molecule directly to damaged heart tissue, promoting repair and improving heart function without affecting the rest of the body.
Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer (TNBC), which is among the most aggressive and difficult-to-treat forms of the disease.
In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in lung cancer. The approach restores drug sensitivity and slows tumor growth. The findings are published in the journal Molecular Therapy Oncology.
University of Kentucky researchers have developed a new experimental model that could point the way toward more effective Alzheimer’s disease treatments by targeting one of the brain’s most important genes for risk and resilience.
FLOWOOD, Miss., Nov. 15, 2025 /PRNewswire/ — Zavation Medical Products, LLC (“Zavation”), a leading innovator in spinal device technology, announces the first successful implantations of the Varisync® ALIF NanoPrime™ System, a next-generation stand-alone ALIF system featuring Zavation’s proprietary titanium ion bond technology.
New platform is designed to enable fast, scalable access to a wide range of AI imaging solutions
The clearance is based on data that included real-world evidence from 1,120 adolescents who received treatment at US TMS centres.
Renu MedTech today unveiled InsuPatch, its tubeless insulin patch pump designed specifically for advancing diabetes care in India.
WARSAW, Ind., Nov. 14, 2025 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of ROSA® Knee with OptimiZe™, an enhanced version of its ROSA® Knee System that offers a more customized experience for surgeons to help deliver accurate and reproducible outcomes1 in robotic-assisted total knee replacement surgery.